Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

20101,782 citationsJournal Articlebronze Open Access

Authors

Alice L. Yu · Genomics Research Center, Academia Sinica

Andrew L. Gilman · Levine Children's Hospital

M. Fevzi Özkaynak · New York Medical College

Wendy B. London · Children's Oncology Group

Susan G. Kreissman · Duke Medical Center

Helen X. Chen · National Cancer Institute

Malcolm A. Smith

Abstract

Immunotherapy with ch14.18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma. (Funded by the National Institutes of Health and the Food and Drug Administration; ClinicalTrials.gov number, NCT00026312.)

Topics & Keywords

Neuroblastoma Research and Treatments Cancer therapeutics and mechanisms Toxin Mechanisms and Immunotoxins

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 363, Issue 14, pp. 1324-1334

DOI: 10.1056/nejmoa0911123

Field-Weighted Citation Impact: 47.37